Vaccine efficacy | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Friday
June 13, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
FRIDAY, JUNE 13, 2025

Vaccine efficacy

A sign of Sinopharm is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the COVID-19 outbreak, in Beijing, China September 5, 2020. REUTERS/Tingshu Wang
Coronavirus chronicle

Peru study finds Sinopharm Covid vaccine 50.4% effective against infections

The study involving Sinopharm's BBIBP-CorV vaccine, which looked at data from February through June at a time when Peru was fighting a brutal second-wave of infections fuelled by the Lambda...

Covaxin demonstrates 93.4% efficacy against severe diseases
Coronavirus chronicle

Covaxin demonstrates 93.4% efficacy against severe diseases

Vials labelled "Astra Zeneca COVID-19 Coronavirus Vaccine" and a syringe are seen in front of a displayed AstraZeneca logo, in this illustration photo taken March 14, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
Coronavirus chronicle

AstraZeneca may have provided incomplete efficacy data from latest Covid-19 trial: NIAID

AstraZeneca logo is reflected in a drop on a syringe needle in this illustration photo taken March 16, 2021. Picture taken March 16, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
Analysis

How worried should we be about reports of blood clots and AstraZeneca's vaccine?

Photo: Collected
Coronavirus chronicle

EU regulator urges caution on Sputnik Covid-19 vaccine

Being vaccinated means you won’t get Covid, right? Not exactly. Photographer: Go Nakamura/Bloomberg
Coronavirus chronicle

I got vaccinated, then I got covid. What happened?

FILE PHOTO: A woman poses for a picture with a cardboard cutout after receiving a dose of COVISHIELD, a COVID-19 vaccine manufactured by Serum Institute of India, at a vaccination centre, after second wave of vaccination started for the elderly with comorbidities, amid the spread of the coronavirus disease (COVID-19) in Mumbai, India, March 1, 2021. REUTERS/Francis Mascarenhas/File Photo
Coronavirus chronicle

Efficacy data for India's own Covid-19 vaccine could boost public acceptance

A health worker prepares an injection with a dose of Astra Zeneca coronavirus vaccine, at a vaccination centre in Westfield Stratford City shopping centre, amid the outbreak of coronavirus disease (COVID-19), in London, Britain, February 18, 2021. REUTERS/Henry Nicholls
Coronavirus chronicle

UK finds vaccines 80% effective at preventing risks in over-80s

Technicians work at Healthcare Maintenance Organisation (HMO) Maccabi's coronavirus disease (COVID-19) public laboratory, performing diverse and numerous tests, in Rehovot, Israel February 9, 2021. REUTERS/Ammar Awad
Coronavirus chronicle

Covid sickness dropped 95.8% after both Pfizer shots: Israeli Health Ministry

Israeli Prime Minister Benjamin Netanyahu receives the second dose of the COVID-19 vaccine at Sheba Medical Center in Ramat Gan, near the coastal city of Tel Aviv, on Jan 9. MIRIAM ALSTER/POOL/AFP VIA GETTY IMAGES
Coronavirus chronicle

What if countries that excel at vaccinations still don’t achieve herd immunity?

Photo provided by Russian Direct Investment Fund (RDIF) shows a researcher working in a laboratory of the Gamaleya Scientific Research Institute of Epidemiology and Microbiology in Moscow, Russia.Photo:Xinhua via UNB
Coronavirus chronicle

EU to launch programme for ‘second generation’ Covid-19 vaccines

FILE PHOTO: An employee holds a vial containing CoronaVac, Sinovac Biotech's vaccine against the coronavirus disease (COVID-19), at Butantan biomedical production center in Sao Paulo, Brazil January 12, 2021. REUTERS/Amanda Perobelli
Coronavirus chronicle

Covid-19 shots might be tweaked if variants get worse

A woman reacts while receiving a vaccination against the coronavirus disease (COVID-19) as Israel continues its national vaccination drive, in East Jerusalem December 23, 2020. REUTERS/Ammar Awad//File Photo
Coronavirus chronicle

Israeli study finds 94% drop in symptomatic Covid-19 cases with Pfizer vaccine

  • Show More
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net